These findings support the hypothesis that tumor-associated macrophages promote cancer progression through STAT3 activation, and CD163 may be used as a potential biomarker to measure M2-type macrophages in iCCA patients and predict clinical outcomes (50). The gene discussed is STAT3; the disease is neoplasm.